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Abstract
Radiotherapy is a treatment choice for local control of breast cancer. However, intrinsic radioresistance of cancer cells limits
therapeutic efficacy. We have recently validated that SCF (SKP1, Cullins, and F-box protein) E3 ubiquitin ligase is an
attractive radiosensitizing target. Here we tested our hypothesis that MLN4924, a newly discovered investigational small
molecule inhibitor of NAE (NEDD8 Activating Enzyme) that inactivates SCF E3 ligase, could act as a novel radiosensitizing
agent in breast cancer cells. Indeed, we found that MLN4924 effectively inhibited cullin neddylation, and sensitized breast
cancer cells to radiation with a sensitivity enhancement ratio (SER) of 1.75 for SK-BR-3 cells and 1.32 for MCF7 cells,
respectively. Mechanistically, MLN4924 significantly enhanced radiation-induced G2/M arrest in SK-BR-3 cells, but not in
MCF7 cells at early time point, and enhanced radiation-induced apoptosis in both lines at later time point. However,
blockage of apoptosis by Z-VAD failed to abrogate MLN4924 radiosensitization, suggesting that apoptosis was not causally
related. We further showed that MLN4924 failed to enhance radiation-induced DNA damage response, but did cause minor
delay in DNA damage repair. Among a number of tested SCF E3 substrates known to regulate growth arrest, apoptosis and
DNA damage response, p21 was the only one showing an enhanced accumulation in MLN4924-radiation combination
group, as compared to the single treatment groups. Importantly, p21 knockdown via siRNA partialy inhibited MLN4924-
induced G2/M arrest and radiosensitization, indicating a causal role played by p21. Our study suggested that MLN4924
could be further developed as a novel class of radiosensitizer for the treatment of breast cancer.
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Introduction
The SCF E3 ubiquitin ligases consist of Skp1, cullins, F-box
proteins, and a RING protein, RBX or ROC. By promoting the
ubiquitination and degradation of various key regulatory proteins,
SCF E3 ligases control several important biological processes
including cell cycle progression, signal transduction and DNA
replication [1,2]. While the substrate specificity of SCF E3s is
determined by the F box proteins that bind to Skp1 and Cullins
through its F-box domain and to substrates through its WD40 or
leucine rich region domains [3,4], the activity of SCF E3 ubiquitin
ligases requires 1) the RING protein RBX or ROC that binds to E2
and facilitates ubiquitin transfer from E2 to substrates [5] and 2)
cullin neddylation, which disrupts inhibitory binding by CAND1
[6,7,8,9]. Accumulated evidence strongly suggests that abnormal
regulation of SCF E3 ubiquitin ligases contributes to uncontrolled
proliferation, genomic instability, and cancer [2], and SCF E3
ligases appear to be an attractive anticancer targets [10,11,12].
Although no specific small molecule inhibitor of E3 ubiquitin
ligases has been successfully discovered and developed [13,14],
MLN4924, a potent small molecule inhibitor of Nedd8 activating
enzyme (NAE) has demonstrated an inhibitory activity against
SCF E3 ligases via inhibiting cullin neddylation [15]. Mechanis-
tically, MLN4924 binds to NAE to create a covalent Nedd8-
MLN4924 adduct that blocks NAE enzymatic activity [16]. By
inactivating SCF E3 ubiquitin ligases, MLN4924 caused the
accumulation of a number of SCF E3 substrates to induce
apoptosis [15,17,18] and senescence [19,20,21], thus inhibiting
tumor growth both in vitro and in vivo. MLN4924 has been
advanced to several Phase I clinical trials [22].
We have recently shown that inactivation of SCF E3 ubiquitin
ligases by siRNA knockdown of either RBX1 or RBX2 (also
known as SAG, Sensitive to Apoptosis Gene) sensitized human
cancer cells to radiation [23,24,25], and that Sag knockout also
sensitized mouse embryonic stem cells to radiation via inducing
apoptosis [26]. Most recently, we found that MLN4924 could act
as a novel radiosensitizing agent by causing accumulation of
CDT1 and WEE1 to enhance radiation-induced DNA damage,
aneuploidy, G2/M arrest and apoptosis in pancreatic cancer cells
[27]. Here we extended our MLN4924-radiosensitization study
PLoS ONE | www.plosone.org 1 March 2012 | Volume 7 | Issue 3 | e34079from human pancreatic cancer cells to breast cancer cells and
reported that MLN4924 is a effective radiosensitizing agent
against breast cancer cells via a p21-dependent mechanism.
Materials and Methods
Compound
MLN4924 was a gift from Millennium Pharmaceuticals, Inc.
(Cambridge, MA) [15]. The compound was dissolved in DMSO to
make a 10 mM stock solution and kept in 220uC before use.
Cell Culture
Breast cancer lines, including SK-BR-3, MCF-7, ZR-75-1 and
T-47D were obtained from ATCC and were grown in DMEM
(Gibco) with 10% fetal bovine serum.
Radiation exposure and clonogenic assay
Cells were seeded in 60-mm dishes at proper cell densities in
duplicate and exposed to different doses of radiation (Philips
RT250, Kimtron Medical) after 24 hrs pre-treatment with
MLN4924, followed by incubation at 37uC for 7 to 11 days.
Survival curves were fitted using the linear-quadratic equation,
and the mean inactivation dose was calculated [28]. Irradiations
were performed in the Experimental Irradiation Core of the
University of Michigan Cancer Center.
siRNA knockdown of p21
The siRNA oligonucleotide target p21 expression is as follows:
si-p21 (59-GUGGACAGCGAGCAGCUGAUU-39), and scram-
bled control siRNA (siCONT: 59-AUUGUAUGCGAUCGCA-
GACUU-39). The oligoes were purchased from Dharmacon
(USA). Cells were transfected with siRNA using Lipfectamine
2000 and split 48 hrs later. One portion was used for clonogenic
assay and the other portion for immunoblotting (IB) [29].
Western blotting
Cells were exposed to various treatments and harvested for
Western blotting as described [29] using antibodies against CDT1,
WEE-1, CUL1 (Santa Cruz Biotechnology), ORC-1, p21, p27 (BD
Biosciences), NOXA (Calbiochem), c-H2AX (MILLPORE), PARP,
Caspase-3, BIM-EL, phospho-CHK1(S345), phospho-CHK2 (T68),
total CHK1 and CHK2 (Cell Signaling), and b-actin (Sigma).
FACS (Fluorescence-activated Cell Sorting) analysis
Cells were treated with MLN4924, or exposed to radiation
alone or in combination. Cells were harvested 24 or 48 hrs post
radiation and analyzed by flow cytometry [29].
DNA fragmentation assay
Cellswereseededin100-mmdishesat0.5610
6cellsperdish,and
pretreated next day with DMSO (control) or MLN4924 (100 nM)
for 6 hrs before being exposed to radiation (6 Gy). The cells were
harvested for48 hrs post radiation by scraping, pelleted and lysed in
600 ml of lysis buffer (5 mM Tris-HCl, pH 8, 20 mM EDTA and
0.5% Triton X-100). The fragmented DNAs in the supernatant
after 14,000 rpm centrifugation were extracted with PCI (Phenol/
Chloroform/Isopropanol) (Fisher) and precipitated with ethanol,
followed by electrophoresis in a 1.8% agarose gel [30].
Statistical analysis
ANOVA were used with SPSS (Statistical Product and Service
Solution) software for statistical comparisons involving multiple
groups, followed by SNK post hoc test to determine significance of
each two group (p,0.05). Paired or unpaired two-tailed Student t
test was performed in comparison between two groups, using SAS
software.
Results
MLN4924 sensitized breast cancer cells to radiation
Our most recent study showed that MLN4924 is a potent
radiosensitizing agent against pancreatic cancer cells [27]. Here
we extended the observation to breast cancer cells. We first
determined the efficacy of MLN4924 in inactivation of SCF E3
ligases as reflected by cullin deneddylation in multiple breast
cancer cells. As shown in Figure 1A, in all tested breast cancer
lines, a portion of cullin-1 was neddylated, and cullin-1
neddylation was completely inhibited after 6 hrs of exposure to
MLN4924 at 1 mM (Figure 1A). We next measured a time-
dependent inhibition of cullin-1 neddylation with a much lower
concentration of MLN4924 and found that MLN4924 at 30 nM
caused a remarkable inhibition of cullin-1 neddylation at 24 hrs,
and a complete inhibition at 72 hrs and thereafter up to 144 hrs
(Figure 1B). We therefore used 30 nM of MLN4924 in our
radiosensitization experiment and found that MLN4924 at such a
low concentration caused a remarkable radiosensitization in SK-
BR-3 cells with a sensitivity enhancement ratio (SER) of 1.75
(Figure 1C). Similar observation was made in MCF7 cells, but to a
lesser extent with a SER of 1.32 (Figure 1C). Thus, we conclude
that MLN4924 is a potent radiosensizer against breast cancer cells.
MLN4924 radiosensitization is associated with enhanced
G2/M arrest and apoptosis
To determine the nature of MLN4924 radiosensitization, we
performed cell cycle profile of two breast cancer cell lines treated
with MLN4924, radiation, alone or in combination using FACS
analysis. As shown in Figure 2A (left panel), treatment with
MLN4924 or radiation for 24 hrs remarkably arrested SK-BR-3
cells (harboring a mutant p53) [31] at the G2/M phase of cell
cycle (43% or 57% vs. control at 19%, respectively). The
combinational treatment further enhanced G2/M arrest with
86% of population arrested in the G2/M. The enhanced G2/M
arrest persisted up to 48 hrs (Figure 2A, right panel). Furthermore,
FACS analysis also showed that radiation, but not MLN4924,
induced apoptosis (as reflected by sub-G1 population) after 24-hrs
treatment, which was not enhanced by MLN4924 at 24-hrs, but
was enhanced at 48-hrs time point (Figure 2B). Consistenly,
significant induction of apoptosis was seen in SK-BR-3 cells
treated with radiation-MLN4924 combination, as demonstrated
by enhanced DNA fragmentation (Figure 2C) as well as PARP
cleavage and caspase-3 cleavage/activation (Figure 2D). However,
in wild type p53-containing MCF7 cells [31], MLN4924 induced
growth arrest at the G2/M phase of cell cycle at either 24-hrs
(45.7% vs. 22.4%) or 48-hrs (56.1% vs. 27.4%) time point, whereas
radiation induced G1 arrest in both time points (63.4% vs. 48.5%
and 57.3% vs. 45.2%, respectively) (Figure 3A). Compared to
MLN4924 treatment alone, MLN4924-radiation combination had
little effect on cell cycle profile (Figure 3A), but did cause a
significant induction of apoptosis (Figure 3B). These results
suggested that radiation-induced disruption of cell cycle progres-
sion in SK-BR-3 cells and apoptotic cell death in both SK-BR-3
and MCF7 cells, can be further enhanced by MLN4924.
Blockage of apoptosis failed to abrogate MLN4924
radiosensitization
Since our recent work showed that activation of caspases,
followed by induction of apoptosis was causally related to
MLN4924 Radiosensitizes Breast Cancer Cells
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breast and head and neck cancer cells [32,33], we next determined
potential causal role of caspase activation/apoptosis induction in
MLN4924 radiosensitization in SK-BR-3. Surprisingly, although
treatment of pan-caspase inhibitor, Z-VAD completely blocked
apoptosis (Figure 4A), it had no effect at all on MLN4924-induced
radiosensitization with SER remained at ,1.7 (Figure 4B). These
results clearly indicated that caspase activation and apoptosis
induction was not causally related to MLN4924 radiosensitization.
MLN4924 had little effect on radiation-induced DNA
damage response, but caused minor delay in DNA repair
Since the major cellular effect of ionizing radiation is to cause
DNA damage and trigger the DNA damage response [34], we,
therefore, examined if MLN4924 treatment would enhance
radiation-induced DNA damage and interfere with the DNA
damage repair process. We first determined the DNA damage
response upon MLN4924-radiation treatment by measuring
phosphorylation of CHK1 and CHK2 and found that while
radiation indeed caused phosphorylation/activation of CHK1 and
CHK2 in both SK-BR-3 and MCF7 cells, MLN4924 had little, if
any, enhancing effect (Figure 5A). In fact, MLN4924 treatment
reduced radiation-induced CHK1 phosphorylation in SK-BR3
cells, consistent with a recent study in which MLN4924 suppressed
CHK1 phosphorylation induced by DNA damage agents, such as
UV and Cisplatin [35]. We next determined DNA double-strand
breaks (DSBs) by measuring the overall levels of c-H2AX protein
at 24 hrs post exposure to radiation or MLN4924, alone or in
combination. We found that while c-H2AX levels increased after
single treatment, the combination treatment caused a further
increase in both breast cancer lines (Figure 5B). Thus, MLN4924
had little role in enhancing radiation-induced DNA damage
response, but did delay DNA repair process, which could
contribute to its radiosensitizing effect.
Figure 1. MLN4924 sensitizes breast cancer cells to radiation. (A&B) Cullin deneddylation: Subconfluent breast cancer cells were treated with
MLN4924 at indicated concentrations or for indicated time periods, followed by immunoblotting (IB) with b-actin as a loading control. (C)
Radiosensitization by MLN4924: SK-BR-3 or MCF7 cells were seeded in 60-mm dishes in duplicate and treated with MLN4924 (30 nM) and radiation at
various doses. The colonies with more than 50 cells were counted after 7–11 days. Surviving fraction was calculated as the proportion of seeded cells
following irradiation to form colonies relative to that of untreated cells (mean 6 SEM) (n=3 for SK-BR-3 cells and n=2 for MCF7 cells). SER was
calculated as the ratio of the mean inactivation dose under untreated control conditions divided by the mean inactivation dose after MLN4924
treatment.
doi:10.1371/journal.pone.0034079.g001
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not other SCF E3 ligase substrates, known to regulate
DNA damage response and apoptosis
To identify potential mediator(s) of MLN4924 radiosensitization,
we measured the levels of proteins known to be a) the substrates of
SCF E3 ligases and b) involved in the regulation of cell cycle
progression (e.g. p21, p27 and WEE1), DNA damage response (e.g.
CDT1 and ORC1), and apoptosis (e.g. NOXA and BIM-EL)
[2,24,36]. We found that as expected, the levels of cell cycle
regulators, such as p21 and WEE1, DNA licencing proteins CDT1
and ORC1, and apoptosis inducer BIM-EL, but not NOXA,
increased substantially upon treatment with MLN4924, but not
radiation (Figure 5C). Unlike what were observed in pancreatic
cancer cells [27], the MLN4924-radiation combination did not
further increase the levels of CDT1 and WEE1, but did caused a
further increase of p21 in both SK-BR-3 and MCF7 cells (Figure 5C).
Thus, p21 is the only SCF E3 ligase substrate, among all tested
substrates, that was induced by either MLN4924 or radiation, leading
to a higher level of accumulation upon combination.
G2/M arrest and radiosensitization by MLN4924 is
partialy inhibited upon p21 siRNA knockdown
Given the fact that MLN4924 enhanced G2/M arrest and
apoptosis by radiation and caused radiosensitization in SK-BR-3
cells (Figure 2), and that p21 was the only SCF E3 substrate whose
accumulation by MLN4924 or radiation was further enhanced by
the combination (Figure 5C), we determined whether accumulated
p21 was causally related to G2/M arrest, apoptosis, and
Figure 2. MLN4924 alters cell cycle profile and induces apoptosis. SK-BR-3 cells were treated with MLN4924 at 100 nM for 24 hrs or 48 hrs
(A&B), alone or in combination with radiation (6 Gy), followed by FACS analysis for cell cycle profile (A), sub-G1 population for apoptosis (B), DNA
fragmentation (48 hrs treatment) (C) and Western blotting with indicated antibodies (D). Shown is mean (A) or mean 6 SEM (B), (n=3): **, p,0.01.
One representative result is shown.
doi:10.1371/journal.pone.0034079.g002
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Upon p21 knockdown (Figure 6A), degree of apoptosis induced by
MLN4924-radiation combination was not changed (Figure 6B), as
compared to the scrambled si-control. The G2/M arrest, however,
was partially reversed from 77.9% to 70.9% at 24 hrs and 77.6%
to 63.9% at 48 hrs (Figure 6C), indicating that p21 accumulation
contributes at least in part to substantial G2/M arrest. More
importantly, MLN4924-induced radiosensitization were remark-
ably inhibited upon p21 knockdown with SER value reduced from
1.54 to 1.2 (Figure 6D). Taken together, these results clearly
suggest a causal effect of p21 accumulation (upon SCF E3
inactivation by MLN4924) on MLN4924-induced G2/M arrest
and radiosensitization in SK-BR-3 cells. On the other hand, the
incomplete rescue of MLN4924-triggered G2/M arrest and
radiosensitization by p21 knockdown might be attributable to a)
incomplete p21 elimination (Figure 6A), b) accumulation of other
yet-to-be identified SCF E3 substrates, and/or c) delayed DNA
repair process (Figure 5B), which was not rescued by p21
knockdown (data not shown).
Discussion
Breast cancer is one of the most frequently diagnosed cancers
and the leading cause of cancer death among women around
world [37]. Although significant advance in the development of
targeted therapy for breast cancer [38], radiotherapy remains to
be an effective option in achieving the local control of the disease,
particularly after conservative surgery [39,40]. However, devel-
opment of radioresistance in breast cancer cells limits the curable
potential and contribute to local recurrences [41,42]. Thus,
development of radiosensitizing agents against breast cancer is in
high demanding for the improvement of therapeutic outcome. To
pursue this end, we have recently found that radioresistant breast
cancer cells can be sensitized to radiation by a small molecule
SMAC mimetic compound SM-164 [32]. The mechanism of SM-
164 radiosensitization was mediated by activation of caspases and
Figure 3. MLN4924 enhances radiation-induced apoptosis.
MCF7 cells were treated with MLN4924 at 100 nM for 24 hrs or
48 hrs (A&B), alone or in combination with radiation (6 Gy), followed
by FACS analysis for cell cycle profile (A) and sub-G1 population for
apoptosis (B). Shown is mean (A) or mean 6 SEM (B), (n=3): **, p,0.01.
One representative result is shown.
doi:10.1371/journal.pone.0034079.g003
Figure 4. Blockage of apoptosis fails to abrogate MLN4924
radio sensitization. SK-BR-3 cells were treated with MLN4924 at
100 nM for 48 hrs, alone or in combination with radiation (6 Gy) in the
absence or presence of pan caspases inhibitor, Z-VAD, followed by DNA
fragmentation (A) or standard clonogenic assay (B). Shown is mean 6
SEM (B) (n=2).
doi:10.1371/journal.pone.0034079.g004
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proteins, cIAP-1 and XIAP [32].
In this study, we tested our working hypothesis that inactivation
of SCF E3 ubiquitin ligases by MLN4924, a small molecule
inhibitor of NAE [15], would sensitize breast cancer cells to
radiation, given the fact that some of SCF E3 components, such as
b-TrCP and SAG, were overexpressed in breast cancer cells which
was associated with chemo- or radio-resistance [24,43]. Indeed, we
showed here that MLN4924 is a potent radiosensitizing agent
against breast cancer cells. Mechanistic study revealed that
although MLN4924 enhanced radiation-induced apoptosis, apop-
tosis induction appeared not to be causally related, since complete
blockage of apoptosis by a pan-caspase inhibitor Z-VAD had no
effect on MLN4924 radiosensitization. Unlike the mechanism by
which MLN4924 sensitized pancreatic cancer cells to radiation via
causing accumulation of CDT1 and WEE1 to trigger DNA
damage response/aneuploidy and G2/M arrest, respectively [27],
MLN4924-induced radiosensitization in breast cancer cells
appeared not to involve CDT1 or WEE1. Instead, it is mediated
at least in part by p21, as demonstrated by 1) either MLN4924 or
radiation induced p21 level, which was further induced by the
combination, and 2) p21 knockdown partially reversed G2/M
arrest and largely abrogated MLN4924 radiosensitization. Thus,
p21 mediated not only MLN4924-induced senescence in HCT116
colon cancer cells and H1299 lung cancer cells [19], but also
MLN4924-induced radiosensitization in SK-BR-3 and MCF7
breast cancer cells.
p21 is a universal inhibitor of cyclin dependent kinases and a
well-known target of p53 [44,45,46]. Activation of p21 mediates
p53 induced growth arrest at both G1 and G2 phases of cell cycle
[47,48]. In response to DNA damage and mitogen starvation, p21
directly interacts and inhibits cyclin A- and cyclin B-associated
Figure 5. MLN4924-radiation triggers DNA damage response and induces accumulation of SCF E3 ligase substrates. Subconfluent SK-
BR-3 and MCF7 cells were treated with MLN4924 (100 nM) or radiation (6 Gy) alone or in combination for indicated time periods up to 48 hrs,
followed by IB analysis using indicated antibodies.
doi:10.1371/journal.pone.0034079.g005
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induction of p21 by radiation could be p53 dependent, as seen in
MCF7 cells harboring a wild type p53 or p53-independent in SK-
BR-3 cells with a mutant p53 [31], through other transcription
factors such as SP1 [53]. Induction of p21 by radiation has been
seen in many other cancer cells, mainly at the transcriptional levels
[54,55], whereas induction of p21 by MLN4924 was likely
mediated by blockage of its degradation, since p21 is well-known
substrate of SCF
Skp2 E3 ubiquitin ligase [2,56]. We observed that
in SK-BR-3 cells, either radiation or MLN4924 caused a
significant G2/M arrest, which was further enhanced by their
combination in which 86% and 72% of cell population was
arrested in the G2/M phase of cell cycle after the treatment for
24 hrs or 48 hrs, respectively (Figure 2A). Partial rescue of G2/M
Figure 6. siRNA knockdown of p21 partially abrogates MLN4924 radiosensitization. SK-BR-3 cells were transfected with siRNA
oligonucleotides targeting p21, along with scrambled control siRNA (siCont). Forty-eight hrs later, one portion of cells was subjected for Western
blotting (A), the other portion was subjected to treatment by MLN4924, radiation or in combination for 24 or 48 hrs, followed by FACS analysis for
sub-G1 apoptotic population (B, mean 6 SD, n=2) or cell cycle profile (C, mean number shown, n=2, C: control, M: MLN4924, I: IR, M+I:
MLN4924+IR). Still other portion was plated for clonogenic assay (D, mean 6 SD, n=3).
doi:10.1371/journal.pone.0034079.g006
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involvement, at least in part, of p21 in the process.
It appeared paradoxical that cells arrested in the G2/M phase
became most sensitive to radiation, given the conventional wisdom
that G2 arrest will allow cells more time to repair damaged DNA,
thus protecting cells. The fact that consistent higher level of
cH2AX, a well-known marker for DNA damage response/repair,
in combination group than that in radiation alone group suggests
that extended G2 arrest, likely resulting from prolonged process of
DNA damage repair, could contribute to MLN4924 radiosensi-
tization. In fact, radiosensitiation of H460 and A549 lung cancer
cells by a tryptamine compound, and of PC-3 prostate cancer cells
by genistein also involved p21 induction and G2/M arrest [57,58].
In summary, our study revealed a potent radiosensitizing
activity of MLN4924, a small molecule inhibitor of SCF E3 ligases,
in breast cancer cells, in addition to our recent observation made
in pancreas and lung cancer cells [27]. Different mechanism of
action for MLN4924 radiosensitization (p21 in breast cancer cells
vs. CDT1 and WEE1 in pancreatic cancer cells) reflected a cell-
line dependent response to inactivation of SCF E3 ligases. Taken
together, our studies provide an appealing piece of evidence for
future development of MLN4924 as a novel radiosensitizing agent
against various human cancers, including breast cancers, with
activated SCF E3 ligases.
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